Annexon(ANNX)

搜索文档
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com· 2024-05-17 04:05
BRISBANE, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 11, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the new ...
Annexon(ANNX) - 2024 Q1 - Quarterly Report
2024-05-14 04:10
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ANNX The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT ...
Annexon(ANNX) - 2024 Q1 - Quarterly Results
2024-05-14 04:05
Exhibit 99.1 Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024; Potential to be the First Targeted Treatment for GBS New Phase 2 Data Showing Neuroprotection of Vision and Vision-Associated Structures by ANX007 in Geographic Atrophy (GA) Presented at ARVO 2024; Initiation of Pivotal Phase 3 ANX007 ARC ...
Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting
Newsfilter· 2024-05-08 00:30
ANX007 demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings ANX007 protected key retinal structures important for vision: significant reduction of photoreceptor loss and meaningful slowing of lesion growth measured by retinal pigment epithelium (RPE) loss in the fovea C1q blockade protected photoreceptor synapses and preserved retinal function in preclinical model, supporting the mechanistic understanding of ANX007 in preserving syna ...
Are Medical Stocks Lagging Annexon (ANNX) This Year?
Zacks Investment Research· 2024-04-17 22:46
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Annexon, Inc. (ANNX) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Annexon, Inc. is a member of the Medical sector. This group includes 1051 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 differ ...
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Newsfilter· 2024-04-17 04:05
BRISBANE, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on April 12, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the ...
Turnstone Biologics Appoints William Waddill to its Board of Directors
Newsfilter· 2024-04-16 21:00
公司任命 - Turnstone Biologics Corp.宣布任命William Waddill为公司董事会成员[1] - William Waddill在生物技术领域拥有三十多年的财务和运营经验[2] 公司业务 - Turnstone Biologics是一家临床阶段的生物技术公司,致力于开发治疗实体肿瘤的新方法[5]
Annexon, Inc. (ANNX) Falls More Steeply Than Broader Market: What Investors Need to Know
Zacks Investment Research· 2024-04-11 07:21
公司股价表现 - Annexon, Inc. (ANNX) 最近的股价为 $6.17,较前一交易日收盘价下跌了 -0.96% [1] - 公司股价在过去一个月上涨了 35.73%,超过了医疗行业的下跌幅度 3.76% 和标普500指数的涨幅 1.78% [2] 财报预测 - 预计 Annexon, Inc. 即将发布的财报将受到投资者的极大关注,预计公司将报告每股收益为 -$0.32,较去年同期增长了 38.46% [3] - 分析师对 Annexon, Inc. 的最新预测修订值得投资者关注,这些修订通常反映了短期业务趋势的变化 [4]
What Makes Annexon (ANNX) a New Buy Stock
Zacks Investment Research· 2024-04-02 01:00
Zacks评级系统 - Annexon, Inc. (ANNX) 最近被升级为 Zacks Rank 2 (Buy)[1] - Zacks评级的核心是跟踪卖方分析师对股票的盈利预期,这对股价有着强大的影响力[2] - Zacks评级系统的升级对于公司盈利前景是一个积极的评论,可能会对股价产生有利影响[4] - Zacks评级系统有效地利用盈利预期修订的力量,与盈利预期修订的趋势之间存在强烈的相关性[7] - Zacks评级系统使用与盈利预期相关的四个因素将股票分类为五组,自1988年以来,Zacks Rank 1的股票平均年回报率为+25%[8] 盈利预期 - 机构投资者对盈利和盈利预期的影响对股价变动有部分贡献[5] - Annexon的盈利预期不断上升,这意味着公司基础业务的改善,投资者对这种趋势的认可应该推动股价上涨[6] - 对于截至2024年12月的财年,预计该公司每股亏损1.48美元,较去年同期报告数字变化16.4%[9] - 过去三个月,分析师一直在提高对Annexon的估计,公司的Zacks共识估计增加了14.2%[10] 股价表现 - Zacks评级系统保持着对其超过4000只股票的“买入”和“卖出”评级的平等比例,只有Zacks覆盖的股票中的前5%获得“强烈买入”评级,接下来的15%获得“买入”评级[11] - Annexon被升级为Zacks Rank 2,使其在盈利预期修订方面位于Zacks覆盖股票的前20%,这意味着股价可能在短期内上涨[13]
Wall Street Analysts Believe Annexon (ANNX) Could Rally 101.12%: Here's is How to Trade
Zacks Investment Research· 2024-04-01 22:56
文章核心观点 - Annexon公司股票近四周上涨20.1%,华尔街分析师短期目标价显示其仍有上涨空间,虽目标价可靠性存疑,但盈利预期上调和Zacks排名表明其短期有上涨潜力 [1][2][5] 分析师目标价情况 - 公司股票近四周涨20.1%,上一交易日收盘价7.17美元,分析师平均目标价14.42美元,潜在涨幅101.1% [1] - 平均目标价由六个短期目标价构成,标准差8.04美元,最低目标价8.50美元,涨幅18.6%,最乐观目标价30美元,涨幅318.4% [1] - 目标价常误导投资者,分析师因业务激励常设定过高目标价,但目标价集中(标准差低)可作为进一步研究起点,投资决策不应仅基于目标价 [3][4] 公司上涨潜力因素 - 分析师对公司盈利前景乐观,近期EPS预估上调,今年过去30天有五个预估上调,无下调,Zacks共识预估提高14.2% [5] - 公司Zacks排名第二(买入),处于基于盈利预估的4000多只股票前20%,表明短期有上涨潜力 [6]